|
TAKAYAMA Yukiko
Department School of Medicine(Tokyo Women's Medical University Hospital), School of Medicine Position Assistant Professor |
|
| Article types | Original article |
| Language | English |
| Peer review | Peer reviewed |
| Title | Gemcitabine plus nab-paclitaxel vs. FOLFIRINOX for patients with advanced pancreatic cancer. |
| Journal | Formal name：Cancer chemotherapy and pharmacology Abbreviation：Cancer Chemother Pharmacol ISSN code：(1432-0843)0344-5704(Linking) |
| Domestic / Foregin | Foregin |
| Volume, Issue, Page | 82(2),pp.245-250 |
| Author and coauthor | TAHARA Junko,SHIMIZU Kyoko,OTSUKA Nao,AKAO Junichi,TAKAYAMA Yukiko,TOKUSHIGE Katsutoshi |
| Publication date | 2018/08 |
| Summary | Although G-nab and FFX are effective treatments for advanced pancreatic cancer, the G-nab group had a higher 1-year survival rate, and G-nab can be more safely administered to older patients. |
| DOI | 10.1007/s00280-018-3611-y |
| PMID | 29846765 |